LUND, Sweden, April 29, 2024 /PRNewswire/ -- Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024..

瑞典隆德，2024年4月29日/PRNewswire/--Immunovia（纳斯达克-斯德哥尔摩：IMMNOV），一家寻求通过早期检测提高胰腺癌生存率的诊断公司，今天宣布，该公司将于2024年5月将其实验室和美国总部迁至北卡罗来纳州的三角研究公园。。

The move to Research Triangle Park follows Immunovia's successful model development study, announced on April 22, 2024, and the successful completion of the discovery phase for its next-generation test in November 2023. Following these successes, the company will focus on confirming the analytical validity of its new test and conducting a large clinical validation study.

迁移至三角研究园之前，Immunovia于2024年4月22日宣布成功进行了模型开发研究，并于2023年11月成功完成了下一代测试的发现阶段。在取得这些成功之后，该公司将专注于确认其新测试的分析有效性，并进行大型临床验证研究。

This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford..

这项工作将在丽莎·福特博士的领导和指导下，在三角研究公园的实验室进行。。

Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs. The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company's existing lab in Marlborough, Massachusetts.

将其实验室和美国总部迁至三角研究园支持Immunovia于2023年7月宣布的战略，以简化运营并降低成本。三角研究公园（RTP）的新空间将比该公司位于马萨诸塞州马尔伯勒的现有实验室小得多，价格也更低。

The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost..

三角研究园较低的劳动力成本应该使公司能够以较低的成本为新实验室配备人员。。

'Research Triangle Park offers access to top talent at a reasonable cost. Moving to a smaller lab in RTP is a key aspect of our ongoing efforts to be a leaner, more efficient company', says Jeff Borcherding, CEO and President of Immunovia.

“三角研究园（Research Triangle Park）以合理的成本为顶尖人才提供了机会。Immunovia首席执行官兼总裁杰夫·博切尔丁（Jeff Borcherding）表示，转移到RTP的一个较小的实验室是我们不断努力成为一家更精简、更有效率的公司的关键方面。

For more information, please contact:Jeff Borcherding CEO and President jeff.borcherding@immunovia.comKarin Almqvist LiwendahlChief Financial Officerkarin.almqvist.liwendahl@immunovia.com +46 709 11 56 08

欲了解更多信息，请联系：Jeff Borcherding首席执行官兼总裁jeff.borcherding@immunovia.comKarinAlmqvist LiwendahlChief金融Officerkarin.almqvist.liwendahl@immunovia.com+46 709 11 56 08

Immunovia in brief

Immunovia简介

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. .

Immunovia AB是一家诊断公司，其使命是通过早期发现提高胰腺癌患者的生存率。Immunovia专注于简单血液检测的开发和商业化，以检测表明高危人群已患胰腺癌的蛋白质和抗体。。

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

Immunovia与医疗保健提供者，领先专家和患者倡导团体合作并参与其中，使其测试可用于胰腺癌风险增加的个人。

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

美国是世界上最大的胰腺癌检测市场。该公司估计，在美国，有180万人患有胰腺癌的高风险，可以从年度监测测试中受益。

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

Immunovia的股票（IMMNOV）在纳斯达克斯德哥尔摩上市。有关更多信息，请访问 www.immunovia.com

This information was brought to you by Cision http://news.cision.com.

此信息由Cision提供给您http://news.cision.com.

https://news.cision.com/immunovia-ab/r/immunovia-streamlines-lab-operations-with-move-to-research-triangle-park--north-carolina,c3969794

https://news.cision.com/immunovia-ab/r/immunovia-streamlines-lab-operations-with-move-to-research-triangle-park--north-carolina，c3969794

The following files are available for download:

以下文件可供下载：

https://mb.cision.com/Main/13121/3969794/2767296.pdf

https://mb.cision.com/Main/13121/3969794/2767296.pdf

Press release (PDF)

新闻稿（PDF）